Scapa Group plc (AIM: SCPA) is today providing a period end update for the six months ended 30 September 2019.
The Group's trading performance for this period is in line with the Board's expectations. On a statutory basis, revenues grew 14.3% (10.4% on a constant currency basis) predominantly driven by Healthcare and the full period effect of the Systagenix technology transfer. Statutory group trading profits reflect the impact of the loss of the ConvaTec contract and are expected to be approximately 17.0% below last year.
H1 Statutory Basis
H1 Continuing Basis²
Organic Growth (excl Syst³ & CVT⁴)
Growth (constant FX)
Growth (constant FX)
Growth (constant FX)
Scapa Group Revenues
Healthcare revenues on a continuing basis are 23.0% ahead of last year (16.7% on a constant currency basis), despite the loss of ConvaTec volumes. On an organic report basis, revenues grew 4.6%, but were broadly flat on constant currency. We anticipate that the second half of the year will benefit from a strong pipeline of new products and technology transfers from new and existing customers. The cost-out related to restructuring of our footprint is in line with expectations.
Industrial revenues increased 3.9% (1.5% on a constant currency basis) despite strong market headwinds, particularly in the automotive sector. We expect the market-wide challenges to continue.
Adjusted net debt at £49.0m reflects the continuing strong cash generation of the Group.
The Board considers Scapa to be well positioned to make further progress against its strategic, operational and financial objectives and remains confident in the Group's outlook.
1Trading profit is before exceptional items, acquisition costs, amortisation of intangible assets and legacy pension costs
²Excluding IFRS 15 provision release. A contract liability provision was created as a result of the acquisition of Systagenix in line with the requirements of IFRS 15 and this is excluded on a 'continuing' basis as it represents a non-cash item. This provision will be released on a straight-line basis over a five-year period, in line with the exclusive supply contract
⁵ Adjusted net debt excludes the £12.0m temporary finance lease for Knoxville site and the impact of IFRS16
For further information:
Scapa Group plc
Heejae Chae - Group Chief Executive
Oskar Zahn - Chief Financial Officer
Tel: 0161 301 7430
Numis Securities Limited
(Nominated Adviser/Joint Broker)
Mark Lander, Freddie Barnfield
Tel: 020 7260 1000
Chris Bowman, Toby Flaux
Tel: 020 3207 7800
Brett Pollard, Victoria Foster Mitchell
Tel: 020 3727 1000
About Scapa Group plc
Scapa Group plc is a diversified Healthcare and Industrial company focused on bringing best-in-class innovation, design and manufacturing solutions to its customers.
Scapa Healthcare is the trusted strategic partner of choice for the world's leading companies in Advanced Wound Care, Consumer Wellness and Medical Device Fixation. We partner with the top global MedTech companies to develop and manufacture innovative skin friendly medical device fixation and topical solutions, from inception through to market delivery, from our state-of-the-art facilities.
Scapa Industrial is a global supplier of bonding solutions and manufacturer of adhesive-based products which offer meaningful value in industrial applications due to their lightweight, easy-to-apply properties. We are recognised for our unparalleled range of products, including adhesive tapes, films and foams, and we can engineer custom designs for even the most unique applications.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...